文献速递糖尿病

达格列净单药或联合艾塞那肽治疗2型糖尿病期间β细胞功能与胰岛素敏感性的变化

Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

本研究纳入90例2型糖尿病患者,在单次给药(急性研究)及治疗1个月和4个月后行180分钟口服葡萄糖耐量试验,比较安慰剂、达格列净、艾塞那肽及达格列净/艾塞那肽对β细胞功能与胰岛素敏感性的影响。结果显示达格列净和艾塞那肽单药均持续改善β细胞功能与胰岛素敏感性,联合治疗改善幅度明显大于任一单药。

要点

  • 急性研究中达格列净、艾塞那肽及联合组校正Matsuda指数均高于安慰剂(P<0.05)。
  • 治疗1和4个月后艾塞那肽组校正Matsuda指数持续升高,达格列净及联合组进一步升高(P<0.001)。
  • 急性研究β细胞功能指数联合组为安慰剂的四倍,高于任一单药。

核心结论

  • 达格列净和艾塞那肽单药治疗均使β细胞功能和胰岛素敏感性持续改善。
  • 达格列净联合艾塞那肽使β细胞功能和胰岛素敏感性的改善幅度明显大于任一单药。

研究设计与样本

  • 共90例患者,急性研究于单次给药后行180分钟口服葡萄糖耐量试验,分组为安慰剂(n=15)、达格列净(n=25)、艾塞那肽(n=25)、达格列净/艾塞那肽(n=25)。
  • 同一批患者还在治疗1个月和4个月后行180分钟口服葡萄糖耐量试验。
  • 计算校正尿糖丢失的Matsuda指数、胰岛素分泌及β细胞功能指数。

主要发现

  • 急性研究校正Matsuda指数:达格列净2.29±0.33、艾塞那肽2.03±0.12、达格列净/艾塞那肽2.36±0.14,均高于安慰剂1.63±0.36(P<0.05)。
  • 治疗1和4个月后,艾塞那肽组校正Matsuda指数保持同样升高,达格列净组和达格列净/艾塞那肽组进一步升高(P<0.001)。
  • 急性研究胰岛素分泌:达格列净组与安慰剂相似,艾塞那肽组和达格列净/艾塞那肽组均高于达格列净组和安慰剂组(P<0.001)。
  • 治疗1和4个月后,艾塞那肽组和达格列净/艾塞那肽组胰岛素分泌仍高于达格列净组(P<0.01)。
  • 急性研究β细胞功能指数:安慰剂0.40±0.04,达格列净0.65±0.10(较安慰剂高62%,P<0.05),艾塞那肽1.17±0.22(为安慰剂三倍),达格列净/艾塞那肽1.69±0.12(为安慰剂四倍),均P<0.001 vs 安慰剂;治疗1和4个月后达格列净组和艾塞那肽组β细胞功能指数进一步升高,达格列净/艾塞那肽组未进一步升高。

临床怎么用

  • 作者结论认为达格列净和艾塞那肽单药治疗使β细胞功能和胰岛素敏感性持续改善,联合治疗使两者改善幅度明显大于任一单药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) alone or with glucagon-like peptide 1 receptor agonists (GLP-1RAs) on β-cell function (BCF) in type 2 diabetes. The hypothesis was that an SGLT2i combined with a GLP-1RA provides superior improvement in BCF than either agent alone. RESEARCH DESIGN AND METHODS: Ninety patients underwent a 180-min oral glucose tolerance test (OGTT) 1) after one drug dose (acute study) (placebo [n = 15], dapagliflozin [n = 25], exenatide [n = 25], and dapagliflozin/exenatide [n = 25]) and 2) after 1 and 4 months of therapy. Corrected Matsuda index (cMI) for urinary glucose loss, insulin secretion, and BCF indices were calculated during OGTT. RESULTS: In the acute study, mean ± SEM cMI in dapagliflozin (2.29 ± 0.33), exenatide (2.03 ± 0.12), and dapagliflozin/exenatide (2.36 ± 0.14) was higher (P < 0.05) than placebo (1.63 ± 0.36). After 1 and 4 months, cMI remained similarly elevated in exenatide and increased further (P < 0.001) in dapagliflozin and dapagliflozin/exenatide. In the acute study, insulin secretion in dapagliflozin was similar to placebo but higher (P < 0.001 vs. both) in exenatide and dapagliflozin/exenatide. After 1 and 4 months in exenatide and in dapagliflozin/exenatide, insulin secretion remained higher (P < 0.01 vs. both) than dapagliflozin. BCF index in the acute study was 0.40 ± 0.04 in placebo, 62% higher (P < 0.05) in dapagliflozin (0.65 ± 0.10), threefold higher in exenatide (1.17 ± 0.22), and fourfold higher in dapagliflozin/exenatide (1.69 ± 0.12) (all P < 0.001 vs. placebo). At 1 and 4 months, BCF rose further in dapagliflozin and exenatide but did not increase further in dapagliflozin/exenatide. CONCLUSIONS: Dapagliflozin and exenatide monotherapy cause sustained improvements in BCF and insulin sensitivity. Combination therapy with dapagliflozin plus exenatide markedly augmented both BCF and insulin sensitivity above that with either agent alone.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Triplitt C, Cersosimo E, Alatrach M, et al. Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes. Diabetes Care. 2025. PMID: 40627548. doi:10.2337/dc25-0490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。